Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Of science interest

<< Previous

Bullboard Posts

Next >>

Comment by CancerSlayeron Dec 19, 2024 1:29pm

127 Views

Post# 36370681

RE:RE:RE:Of science interest

DJDawg wrote:
That meant to be a dash.

No intervention = a certain amount of reactive oxygen (always some in all cells)= 1
Ruth/Rad = 1.6 times the reactive oxgyen of control baseline
Ruth/Rad/Met = 2.4 times the reactive oxgyen of control baseline

Reactive oxgyen, once released inside a cell is highly damaging and destructive. So much so that cells often die quickly due to internal disruption

And like in war, the larger & more rapid the response, the bigger your advantage. IV Rutherrin can reach the more deep-seated cancer cells, & by maximizing its activation by a proper source(s), you stay one step ahead of the enemy by decreasing its ability or likelihood to mount an adequate defense (an antioxidant defense system in cancer's case).

The above also underscores the more effective killing potential of combo therapies that can synergize & more rapidly overwhelm cancer before it has the opportunity to resist or hide. The competition's never-ending treatment protocols (with their prolonged maintenance/reinduction schedules) not only exhaust/exasperate the patient, they can promote/strengthen treatment-resistant cancer cells imo, hence one can see the relatively large drop-offs in the duration of response.

Hopefully, this company gets their BTD app in order & can loosen its organizational/operational grip at the right moment for shareholders.

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features